INHIBITORS OF BRUTON'S TYROSINE KINASE: THE INCREASING SIGNIFICANCE IN TARGETING B-CELLS IN MULTIPLE SCLEROSIS

B. Saisreevardhan*, N. Spoorthi, Dr. Mohammed Rasheed

ABSTRACT

Demyelination of nerve fibers and progressive neurological deterioration are hallmarks of Multiple Sclerosis (MS), a chronic, inflammatory, and neurodegenerative disease of the central nervous system (CNS). Since B-cells are thought to play a major part in the pathophysiology of MS, treatments that specifically target these cells have been developed. Bruton's Tyrosine Kinase (BTK) inhibitors have become a viable treatment choice among them. This article examines the clinical effectiveness, mechanism of action, and future prospects of BTK inhibitors in the management of multiple sclerosis.

Keywords: Since B-cells are thought to play a major part in the pathophysiology of MS, treatments that specifically target these cells have been developed.